Related Experiment Videos
Recombinant human relaxin as a cervical ripening agent
J E Brennand1, A A Calder, C R Leitch
1Department of Obstetrics and Gynaecology, University of Edinburgh, UK.
British Journal of Obstetrics and Gynaecology
|July 1, 1997
Summary
Recombinant human relaxin (rhRIx) gel did not improve cervical ripening for labor induction in term pregnancies. This study found no significant benefits in labor progression or outcomes when using rhRIx as a cervical ripening agent.
Area of Science:
- Reproductive Medicine and Obstetrics
- Pharmacology and Therapeutics
Background:
- Cervical ripening is crucial for successful labor induction in term pregnancies.
- Pharmacological agents are commonly used to facilitate cervical ripening.
- Recombinant human relaxin (rhRIx) is a potential agent for cervical ripening.
Purpose of the Study:
- To evaluate the efficacy and safety of intravaginal recombinant human relaxin (rhRIx) gel.
- To assess rhRIx as a cervical ripening agent in women with an unfavorable cervix before labor induction at term.
Main Methods:
- A multi-center, double-blind, placebo-controlled trial.
- Ninety-six women at 37-42 weeks gestation with a modified Bishop score ≤ 4 were randomized.
- Participants received intravaginal rhRIx gel at doses of 0, 1, 2, or 4 mg.
Main Results:
- No significant difference in the change of modified Bishop score across all treatment groups.
- Similar lengths of the first and second stages of labor, PGE2 and oxytocin requirements, and mode of delivery.
- No evidence of systemic absorption of relaxin when administered via intravaginal gel.
Conclusions:
- Intravaginal recombinant human relaxin (rhRIx) gel, at doses of 1-4 mg, demonstrated no efficacy as a cervical ripening agent.
- rhRIx did not alter cervical status or influence labor progression in women undergoing labor induction at term.